Figures & data
Figure 1. HIFU ablation of two nanoparticle delivery. (a) Synthetic procedures for Antibodyobot and Bifidorobot. (b)Targeting of tumor tissue. (c) HIFU ablation.
Figure 2. Morphology and characterization. (a) OM of PFH/BL-NPs. (b,c) TEM of PFH/BL-NPs. (d) TEM of BL-NPs, the red arrow refers to the liposome membrane and the blue arrow refers to the bubble. (e) Size distribution of BL-NPs (n = 3). (f) Zeta potentials of PFH/BL-NPs (n = 3). (g) Size distribution of PFH/BL-NPs (n = 3). (h) Zeta potentials of PFH/BL-NPs (n = 3).
Figure 3. In vitro conjunction of PFH/BL-NPs and B. longum. (a) CLSM images of DiI-labeled PFH/BL-NPs, FITC-labeled B. longum and Bifidorobot. (b,c) FCM images of binding efficiencies of PFH/BL-NPs and B. longum (n = 3). (d) Growth characteristics of B. longum and B. longum + Antibodyobot in vitro (n = 3).
Figure 4. Targeting ability of Bifidorobot and Antibodyobot in vivo. (a) Fluorescence images of Bifidorobot and B. longum + Antibodyobot group at pre, 24 h, 48 h, 72 h, and 96 h of injection. (b) Quantification of fluorescence intensity at the tumor site (n = 10, *p < .05). (c) Frozen slice of PFH/BL-NPs, Bifidorobot and B. longum + Antibodyobot group at 48 h after injection (n = 6).
Figure 5. Synergistic HIFU treatment in vivo. (a) Ultrasonic gray scale changes before and after HIFU ablation. (b) Coagulative necrosis of tumors by TTC staining after HIFU therapy. (c) Quantitative analysis of ablated volume (n = 10, ***p < .001). (d) Quantitative analysis of gray scale values (n = 10,***p < .001).
Figure 6. Bifidobacterium longum effects on HIF-1α expression in tumors. (a) Expression of HIF-1α in tumors at different times after injection of B. longum and PBS. (b) Quantitative analysis of average optical density value of HIF-1α-positive expression in each group (n = 3, **p < .001,****p < .0001).
